ISRCTN53872240已完成不适用
A randomised phase II study of doxorubicin combined with thalidomide versus doxorubicin alone for patients with unresectable hepatocellular carcinoma
Erasmus Medical Centre (Netherlands)0 个研究点目标入组 30 人开始时间: 2006年1月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically proven HCC
- •2. Irresectable tumour
- •3. Failure to previous treatment
- •4. World Health Organization (WHO) performance status 0 - 2
- •5. At least 4 weeks since prior treatment with HMG-Coa reductase inhibitors or systemic immunosuppresiva
- •6. Adequate hepatic and bone marrow function
排除标准
- •1. Prior treatment with doxorubicin or thalidomide
- •2. Uncontrolled hypertension
- •3. Unstable angina
- •4. Arrhythmias requiring treatment
- •5. Myocardial infarction (MI)
- •6. Thrombo-embolic events requiring treatment
- •7. Congestive heart failure or cardiomyopathy requiring treatment
- •8. Peripheral neuropathy
研究者
相似试验
招募中
不适用
A randomized phase II study of doxorubicin combined with thalidomide versus doxorubicin alone for patients with unresectable hepatocellular carcinoma.hepatocellular cancerNL-OMON21497ot applicable30
进行中（未招募）
不适用
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancereoadjuvant chemotherapy in operable breast cancerMedDRA version: 14.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000021-32-ITELI LILLY256
进行中（未招募）
1 期
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer - N/AFemales with histologically confirmed diagnosis of primary early breast cancer, with a tumor size = 2 cm, of Stages T2-T4/N0-2/, as confirmed by incisional or core biopsy M0 will be treated with chemotherapy prior to surgery..EUCTR2005-000021-32-ESilly S.A.256
进行中（未招募）
不适用
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer - S080Females with histologically confirmed diagnosis of primary early breast cancer, with a tumor size = 2 cm, of Stages T2-T4/N0-2/, as confirmed by incisional or core biopsy M0 will be treated with chemotherapy prior to surgery..EUCTR2005-000021-32-DEEli Lilly and Company Limited256
Unknown
2 期
Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast TumorBreast CancerNCT01176799National University Hospital, Singapore73